Related Experiment Videos
What preclinical data are needed to justify once-daily therapy?
1Department of Microbiology, Faculty of Medicine, Laval University, Québec, Canada.
Journal of Clinical Pharmacology
|August 1, 1992
Summary
Once-daily antimicrobial dosing requires careful consideration of pharmacodynamics. Animal models show that once-daily therapy offers superior microbial killing compared to other dosing schedules.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Optimizing antimicrobial therapy involves understanding drug-bug interactions at infection sites.
- Ideal antimicrobial agents exhibit concentration-dependent killing and a significant post-antibiotic effect.
- Pharmacokinetic properties must ensure a favorable therapeutic ratio (concentration/MIC) at the infection site.
Purpose of the Study:
- To evaluate the impact of antimicrobial dosage schedules on therapeutic outcomes.
- To compare the pharmacodynamics of various antibiotics at different dosing intervals.
Main Methods:
- Utilized an animal model with infected fibrin clots to assess antimicrobial efficacy.
- Evaluated key pharmacokinetic and pharmacodynamic parameters including peak levels, half-life, area under the curve, and time above minimum inhibitory concentration (MIC).
Main Results:
- Once-daily antimicrobial administration demonstrated superior microbial killing compared to alternative dosing regimens.
- Aminoglycosides and quinolones appear more suitable for once-daily dosing than beta-lactams, unless the latter possess an extended half-life.
Conclusions:
- Dosage scheduling significantly influences antimicrobial efficacy.
- Once-daily dosing strategies, particularly with agents like aminoglycosides and quinolones, may enhance treatment outcomes by optimizing pharmacodynamic parameters.